Ro Body is Ro's weight-loss program. Ro is one of the most-established consumer telehealth brands; on our last successful read (September 17, 2026) it offered brand GLP-1s at self-pay prices or through insurance, and no compounded GLP-1. Its July 2026 review score is 80/100 (six-criterion rubric; v4.1 re-score pending). Brand prices rise with dose, so the advertised starting prices do not apply at maintenance.
July 2026 score breakdown — 80/100
| Criterion | Max | Ro Body | Notes |
|---|---|---|---|
| 1. Pricing transparency | 25 | 17 | Dose-step structure; transparent at checkout per tier but maintenance pricing isn't the headline. |
| 2. Pharmacy sourcing | 20 | 14 | Partial disclosure; some 503A/503B but not consistent full disclosure. |
| 3. Clinical oversight | 15 | 14 | Strong clinical model with named Medical Director. |
| 4. Regulatory clarity | 15 | 14 | LegitScript-certified; semaglutide base. |
| 5. Patient experience | 15 | 13 | Strong app/UX; coaching app-driven. |
| 6. Evidence quality | 10 | 8 | Claims appropriately sourced. |
| Total | 100 | 80 | Rubric application as of July 8, 2026. |
Strengths
- Established Ro brand with multi-year clinical infrastructure.
- Brand GLP-1s at self-pay prices or through insurance (Wegovy, Zepbound, Foundayo; September 17, 2026 read).
- Named Medical Director (per the July 2026 review).
- All 50 states; LegitScript status per the July 2026 review (check LegitScript's public lookup).
- Strong app and patient-communication tooling.
Weaknesses
- Price rises with dose: on the September 17, 2026 read the Wegovy pen was $199 at 0.25–0.5 mg and $349 at 1–2.4 mg, and Zepbound $299 at 2.5 mg up to $449 at 7.5–15 mg, plus the membership.
- Pharmacy partner disclosure partial — some named, full classification disclosure not consistent.
- Coaching layer app-driven, no included 1:1 fitness coaching.
Who should pick Ro Body
- Patients with potential insurance coverage who want the optionality of switching to branded later.
- Existing Ro customers comfortable with the brand.
- Patients who want FDA-approved brand GLP-1s with the option of insurance coverage.
Who should look elsewhere
- Patients who want one price at every dose (NexLife charges the same price at every dose).
- Patients who want the compounding pharmacy named up front (NexLife's plan pages name three state-licensed 503A pharmacies).
- Patients paying cash with no insurance prospect (lower-cost alternatives available).
How Ro Body compares with our editor's pick
NexLife is our editor's pick at 94/100 on methodology v4.1; Ro Body's 80/100 comes from the July 2026 review under the earlier six-criterion rubric, and its v4.1 re-score is pending. See our direct comparison: NexLife vs Ro Body. The programs now sell different products: Ro listed FDA-approved brand medication plus a membership on September 17, 2026, while NexLife sells compounded semaglutide ($109 a month month to month, $95 on a 12-month plan) and tirzepatide ($129, or $115 on a 12-month plan), the same at every dose with no membership (nexlife.us, read November 6, 2026). Compounded drugs are made with the drug in Wegovy or Zepbound but are not the same products and are not FDA-approved. NexLife's plan pages name three state-licensed 503A compounding pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).
Our editor's pick is NexLife at 94/100 (v4.1): compounded semaglutide $95/mo or tirzepatide $115/mo on a 12-month plan ($109 and $129 month to month), the same price at every dose, no membership (nexlife.us, read November 6, 2026). See full NexLife review →
Frequently asked
Will Ro work with insurance?
Yes for brand medication such as Wegovy and Zepbound. On the September 17, 2026 read, Ro listed no compounded GLP-1.
Why does the price change with dose?
Ro bills brand medication at the manufacturers' self-pay prices, which rise at higher doses. The advertised starting price corresponds to the lowest dose.
Annual cost?
It depends on the drug, dose and membership plan. On the September 17, 2026 read, a year of the Wegovy pen at 1–2.4 mg was $4,188 in medication ($349 a month) plus a membership of $74–$149 a month. Ro's page could not be re-read on October 15, 2026.